

“Casting” light on the role of glycosylation during embryonic development: Insights from zebrafish

Heather R. Flanagan-Steet · Richard Steet

Received: 14 March 2012 / Revised: 23 April 2012 / Accepted: 25 April 2012 / Published online: 26 May 2012
© Springer Science+Business Media, LLC 2012

Abstract Zebrafish (*Danio rerio*) remains a versatile model organism for the investigation of early development and organogenesis, and has emerged as a valuable platform for drug discovery and toxicity evaluation [1–6]. Harnessing the genetic power and experimental accessibility of this system, three decades of research have identified key genes and pathways that control the development of multiple organ systems and tissues, including the heart, kidney, and craniofacial cartilage, as well as the hematopoietic, vascular, and central and peripheral nervous systems [7–31]. In addition to their application in large mutagenic screens, zebrafish has been used to model a variety of diseases such as diabetes, polycystic kidney disease, muscular dystrophy and cancer [32–36]. As this work continues to intersect with cellular pathways and processes such as lipid metabolism, glycosylation and vesicle trafficking, investigators are often faced with the challenge of determining the degree to which these pathways are functionally conserved in zebrafish. While they share a high degree of genetic homology with mouse and human, the manner in which cellular pathways are regulated in zebrafish during early development, and the differences in the organ physiology, warrant consideration before functional studies can be effectively interpreted and compared with other vertebrate systems. This point is particularly relevant for glycosylation since an understanding of the glycan diversity and the mechanisms that control glycan biosynthesis during zebrafish embryogenesis (as in many organisms) is still developing.

Nonetheless, a growing number of studies in zebrafish have begun to cast light on the functional roles of specific classes of glycans during organ and tissue development. While many of the initial efforts involved characterizing

identified mutants in a number of glycosylation pathways, the use of reverse genetic approaches to directly model glycosylation-related disorders is now increasingly popular. In this review, the glycomics of zebrafish and the developmental expression of their glycans will be briefly summarized along with recent chemical biology approaches to visualize certain classes of glycans within developing embryos. Work regarding the role of protein-bound glycans and glycosaminoglycans (GAG) in zebrafish development and organogenesis will also be highlighted. Lastly, future opportunities and challenges in the expanding field of zebrafish glycobiology are discussed.

Keywords Zebrafish · Glycosylation · Development · Sialylation · Glycosaminoglycans · N-glycans · Mucins · Cartilage

Structural diversity and developmental expression of glycans in zebrafish

While the earliest functional studies focused on the role of individual enzymes and structures, more recent MS-based analyses of zebrafish glycoconjugates have yielded a better appreciation of the glycan diversity in the organism. Leading the way, Khoo and colleagues described the major protein- and lipid-bound zebrafish glycans present in fertilized eggs and early (<48 h post-fertilization; hpf) embryos [37]. These analyses demonstrated that zebrafish embryos exhibit surprising structural diversity, particularly with regard to sialylation profiles. Complex and oligomannose N-glycans, which are abundant in embryos at all developmental stages, bear a wide range of monosialylated and oligosialylated termini that include Neu5Ac and Neu5Gc. This high degree of sialylation in zebrafish embryos was exemplified by the fact that the only non-sialylated structures

H. R. Flanagan-Steet · R. Steet (✉)
Complex Carbohydrate Research Center, University of Georgia,
Athens, GA 30602, USA
e-mail: rsteet@ccrc.uga.edu

detected were high mannose type N-glycans. The most common complex N-glycans were those terminating in the unusual motif, Gal β 1-4(Neu5Ac/Gc)Gal β 1-4(Fuc α 1-3)GlcNAc (Fig. 1). Along with core 1 and core 2 O-glycan structures common to mammalian tissues, abundant and unusual fucosylated mucin-type O-glycans were also observed (Fig. 1). Oligosialylation of this unusual core structure was noted but appeared to be restricted to the earliest development stages (<24hpf). Analyses of glycolipids in this study also led to the identification of a heterogeneous family of oligosialylated lactosylceramide compounds that appear only at later development stages (>24hpf). Together, these studies suggest a complex pattern of sialylation of both proteins and lipids during zebrafish embryogenesis and provided a starting point to explore the activity and expression of specific sialyltransferase families [38–42]. The recent glycomic profiling of a zebrafish liver cell line revealed a relatively simple panel of glycans, highlighted by the presence of multisialylated N- and O-glycans with the same unusual epitopes described above as well as sialylated gangliosides [43]. Characterization of the glycosyltransferases in this cell system showed that these glycan profiles correlated well with the expression patterns of all putative sialyl- and fucosyltransferases. This cell system will provide a valuable tool to study the regulation of glycosylation and the function of glycans in zebrafish.

Phylogenetic and expression studies aimed at defining the sialyltransferase families have now been reported, lending some insight into the origin of the unique sialylation profile in zebrafish. All six ST8Sia, which are temporally regulated, exhibit distinct and overlapping patterns of expression in the embryonic central nervous system, suggesting an important role for the α 2-8-sialylated compounds in its development [39]. Glycoproteins and glycolipids also differ by the extent and the nature of their substituting oligosialylated sequences, demonstrating that α 2-8-linked sialylation was differentially regulated in these glycan classes during development [38]. The duplicated paralogs, *ncam1a* and *ncam1b*, appear to be major carriers of

polysialic acid in zebrafish. Moreover, the distinct expression patterns of these paralogs within the embryo suggest diverse functions within the central and peripheral nervous system [44]. Surprisingly, two functional CMP-sialic acid synthetases (*cmas1* and *cmas2*) have also been identified in zebrafish, one of which is exclusively localized to the cytosol [45]. These enzymes exhibit different substrate specificities as *cmas1* binds to Neu5Ac with high affinity and *cmas2* favors 5-deamino-neuraminic acid (Kdn). Further investigation will no doubt identify other examples of subfunctionalization within the glycosylation machinery of zebrafish.

The regulation of fucosylation in zebrafish embryos has also been characterized. This modification appears to correspond with the increase in the formation of complex type glycans by 12 hpf [46]. Seminal work by Hase and colleagues demonstrated activity of two α 1,3-fucosyltransferases in zebrafish capable of generating Lewis x fucosylation [47]. The expression of these enzymes is tightly regulated and is restricted to the segmentation period of embryogenesis. Interestingly, the Lewis x epitope produced by zebrafish fucosyltransferases was found in abundance on free oligosaccharides, generated by the hydrolysis of glycoproteins by endogenous glycosidases [48].

Mass spectrometric studies have begun to elucidate the structural diversity of GAGs in zebrafish. Despite early reports suggesting that zebrafish lack heparan sulfate-containing proteoglycans [49], subsequent analysis demonstrated that developing embryos contain both chondroitin and heparan sulfate, and that expression of these GAGs is temporally and spatially regulated [50]. Chitin oligosaccharides have also been detected in zebrafish. The synthesis of these Nod-like structures was shown to be restricted to very early stages of development and was tied to the presence of a zebrafish homolog of the *Xenopus* developmental gene DG42 [51]. These oligosaccharides appear to have roles in early development as disruption of their synthesis leads to gastrulation defects [52, 53]. At least some of these effects appear to be due to the ability of the chitin oligosaccharides to activate ERK pathways [54].




Fig. 1 The structures of the abundant and unusual O-glycans (*top*) and N-glycans (*bottom*) isolated from zebrafish embryos

Visualizing glycans in zebrafish

The use of lectins, such as *Maclura pomifera*, peanut agglutinin, and wheat germ agglutinin, to mark specific developmental stages or processes ranging from oogenesis to chondrogenesis and neurogenesis is well established and provided the earliest indications that glycan expression is dynamic during zebrafish embryogenesis [55–57]. More recently, advances in chemical biology methods have enabled specific classes of glycans to be visualized in living zebrafish embryos. Utilizing a powerful combination of metabolic labeling, click chemistry and confocal microscopy, Bertozzi

and colleagues demonstrated that the biosynthesis of GalNAc-containing glycans, primarily mucin-type O-glycans, during zebrafish development is a highly dynamic and tissue-specific process [58]. Increases in *de novo* glycan biosynthesis at discrete stages were detected in the craniofacial region, pectoral fins, and olfactory organs. Furthermore, differential rates of glycan endocytosis were observed within certain embryonic tissues, providing novel insights into the tissue-specific expression and trafficking of glycans. Subsequent work showed that mucin-type O-glycans could be detected as early as 7hpf, during the gastrula stage of development. Live analysis of glycan trafficking revealed dramatic reorganization of glycans, including their rapid migration toward the cleavage furrow of mitotic cells [59]. Related studies have employed analogous approaches with different azide-modified monosaccharides to visualize fucosylated, sialylated and polylectosamine glycans in zebrafish [60–64]. We envision that this methodology will find highly useful applications in the context of the glycosylation-related zebrafish mutants and models discussed below.

Role of glycans in zebrafish development

A role for specific protein and lipid-bound glycans during zebrafish development has been uncovered by work using transient morpholino (MO)-driven knockdown and stable genetic mutants of the glycosyltransferases and the nucleotide-sugar transporters involved in their synthesis (Table 1). Among these, the *slytherin* (*srn*) mutant, which bears a missense mutation in the rate-limiting enzyme of GDP-fucose biosynthesis (GDP-mannose 4,6-dehydratase or *gmds*), demonstrated that defective protein fucosylation causes several neuronal phenotypes [65]. These phenotypes included alterations in neurogenesis and gliogenesis, defects

in axonal path finding and arborization, and abnormal formation of both neuromuscular and central nervous system synapses [66]. Analogous to *Drosophila* mutants within the same pathway, several of these phenotypes were shown to be dependent on decreased Notch signaling. Importantly, the Notch receptor bears both N- and O-linked fucosylated glycans, and manipulation of these glycans has been shown to alter propagation of downstream signals [67–70]. Some of the *srn* phenotypes, in particular those affecting retinotectal connectivity, appear to be Notch-independent. Analysis of another mutant allele of *gmds*, *towhead* (*twd*), showed that fucosylated glycans expressed in neuroepithelial cells are required to guide the migration of vagus motor neuron progenitors [71]. As with the *srn* retinotectal defects, these phenotypes were also independent of changes in Notch signaling. In an effort to assign *twd* phenotypes to the generation of a particular type of fucosylated glycan, the authors also used MOs to knockdown expression of several fucosyltransferases, including *pofut1*, *pofut2*, *ft1*, *ft2*, *fut7-9*, and *fut10*; among these only *fut10* (which itself did not fully phenocopy *twd*) affected vagus motor neuron development. A role for core fucosylation during midline patterning and retinal and motor neuron development has also been demonstrated. Knockdown of *fut8*, as well as one of the principal *fut8* substrates, apolipoprotein B (ApoB), phenocopies defects noted in mutants of Sonic Hedgehog (Shh) signaling (*smu*, *syu*, *yot*) [72]. As had previously been demonstrated in *Drosophila*, these results indicate that altered core fucosylation of ApoB impacts Shh signaling, possibly by affecting its transport.

Depletion of other glycosyltransferases, including two β 1,4-galactosyltransferases (β 4Galt1, β 4Galt5) has provided insight into the functional relevance of galactosylation during early aspects of zebrafish development. Morpholino knockdown of β 4Galt1 resulted in aberrant convergent

Table 1 Known zebrafish glycosylation mutants

Glycan Type/Modification	Mutant Name	Gene	Primary Phenotypes
Fucosylation	<i>slytherin</i> (<i>srn</i>)	<i>gmds</i>	Defects in neurogenesis, gliogenesis, axonal pathfinding, and synapse formation [ref 65, 66]
	<i>towhead</i> (<i>twd</i>)	<i>gmds</i>	Altered migration of vagus motor neuron progenitors [ref 71]
GAG biosynthesis	<i>dackel</i> (<i>dak</i>)	<i>ext2</i>	Altered cartilage development, reduced osteoblast differentiation, optic tract missorting [ref 93, 94]
	<i>boxer</i> (<i>box</i>)	<i>extl3</i>	Optic tract missorting [93]
	<i>xylt1</i>	<i>xylt1</i>	Altered craniofacial chondrogenesis and accelerated osteogenesis [ref 92]
Nucleotide-sugar biosynthesis	<i>jekell</i> (<i>jek</i>)	<i>udgh</i>	Defects in craniofacial and cardiac valve formation [ref 91]
	<i>perplexed</i> (<i>per</i>)	<i>cad</i>	Abnormal craniofacial formation [ref 82]
	<i>man 'o war</i> (<i>mow</i>)	<i>uxs1</i>	Defects in craniofacial and cardiac valve formation, decreased osteogenesis [ref 90]
GAG modifying enzymes	<i>fam20b</i>	<i>fam20b</i>	Altered chondrogenesis and accelerated osteogenesis [ref 92]
	<i>pinscher</i> (<i>pic</i>)	<i>papst1</i>	Altered chondrogenesis and osteogenesis [ref 94]

extension movements during gastrulation [73], and similar reductions in β 4GalT5 affected dorsoventral patterning of embryos by a Bmp2-dependent mechanism [74]. In the latter case, the authors suggest that aberrant galactosylation of proteoglycans, and not N-glycans or glycolipids, is responsible for the altered Bmp2-dependent signaling. Work by Vasta and colleagues have highlighted a role for galactose-binding galectins during zebrafish embryogenesis. The expression of this family of lectins is developmentally regulated and functional studies indicate important functions for galectins during gliogenesis, skeletal muscle development and the regeneration of rod photoreceptors [75–79]. The presence and abundance of the unusual terminal galactose-bearing N-glycans in zebrafish embryos may therefore be important with regard to the function of these galectins.

Substantial work has also been done to study the expression and function of polysialylation in zebrafish. Differential expression of multiple polysialyltransferases (*stx/St8sia2* and *pst/St8sia4*) has been linked to neuronal migration and plasticity in the brains of developing and adult zebrafish, respectively [42]. Further, enzymatic removal of polysialylation adversely affects pathfinding of a subset of commissural axons within the developing midbrain and hindbrain [80]. Interestingly, morpholino knockdown of the single *St8sia3* gene, which was heavily expressed in somitic musculature, led to anomalous myotomal morphologies, including defects in the architecture of the segment boundaries and integrity of the myotendonous-junction [41]. These myotomal defects were accompanied by altered projection of innervating motor axons. Although *St8sia3* is clearly expressed in the musculature and the phenotypic data provide compelling evidence of a novel non-neuronal role for *St8sia3*, it is currently unclear whether the somitic phenotypes are independent of the axonal defects.

Cytosolic glycosyltransferases, such as O-GlcNAc transferase (*ogt*), have also been studied in zebrafish [81]. Overexpression of *Ogt* or O-GlcNAcase (*oga*) resulted in embryos with shortened body axes, reduced brain size and increased rates of cell death. *Ogt/Oga* overexpression also delayed epiboly and caused disorganization of the cytoskeleton within the yolk syncytial layer. Lastly, enzymes that indirectly affect glycosylation have also been characterized in zebrafish mutants. The *perplexed* mutant harbors a mutation in the metabolic enzyme carbamoyl-phosphate synthetase2-aspartate transcarbamylase-dihydroorotase (*cad*) gene [82]. This enzyme is required for *de novo* synthesis of pyrimidines used for UDP-dependent protein glycosylation. Although overall pyrimidine metabolism is likely affected in the *perplexed* mutant, the craniofacial phenotypes noted were highly similar to the UDP-glucuronic acid/UDP-N-acetylgalactosamine dual transporter mutant (*hi3378*), suggesting that deficient glycosylation is a contributing factor in the onset of these phenotypes.

Role of GAGs in zebrafish development

Arguably the largest body of work to date on the role of glycoconjugates during zebrafish development encompasses defects in the synthesis and modification of GAGs. The vast number of identified zebrafish mutants affecting synthesis of heparan sulfate (HS), chondroitin sulfate (CS) and hyaluronic acid (HA) underscores the importance of these carbohydrates during development [83]. The role of this class of glycans in embryogenesis was initially revealed following enzymatic removal of specific GAGs in developing embryos [84, 85]. Functional roles for several proteoglycan core proteins in zebrafish development have also been described but will not be covered in detail here [86–89]. The repertoire of existing mutations affect all aspects of GAG synthesis, including the production the sugar nucleotide precursors (*uxs1*, *udgh/jek*) [90, 91], the glycosyltransferases responsible for GAG synthesis (*ext2/dak*, *extl3/box*, *xyll1*) [92–94], and the proteins involved in their sulfation or phosphorylation (*papst1/pic*, *C4ST-1*, *fam20b*) [92, 94, 95]. Loss of these enzymes results in defects affecting a number of processes including craniofacial chondrogenesis, skeletogenesis, cardiac valve formation, and multiple aspects of axon guidance. In several cases, including *uxs1*, *udgh/jek*, *xyll1*, *fam20b*, *ext2/dak*, and *pic*, altered synthesis or modification of GAGs has been shown to affect morphogenesis and/or maturation of the craniofacial chondrocytes. In addition to altered chondrogenesis, several of these mutants also exhibit defects in bone formation, as evidenced by changes in the expression of bone markers, such as *runx2b* and *osterix*, or Alizarin red staining. In the cases of *uxs1*, *dak*, and *pic*, loss of GAG expression decreased osteogenic processes. In contrast, chondrocyte maturation, osteoblast differentiation and bone formation were actually accelerated in the *xyll1* and *fam20b* mutants [92]. Reduced GAG synthesis also adversely affects cardiac valve formation. In the *udgh* mutant *jek* (defective in CS, HS and HA production), cells at the border of the atrial and ventricular chambers do not differentiate from their endocardial neighbors, and as such cardiac cushion and ultimately valve formation fail. Similarly, Peal *et al.* demonstrated that chemical or genetic inhibition of CS biosynthesis also perturbed these processes [83]. In this case, the authors demonstrate that in zebrafish the gelatinous matrix, or cardiac jelly, required for atrioventricular valve formation is rich in chondroitin sulfate GAGs, and their depletion impairs valve cell migration and cushion formation. Decreased expression of an accessory component, the *dfna5* deafness gene, which was shown to regulate the expression of *udgh*, also resulted in craniofacial and ear defects that phenocopy the *jek* mutant [96].

Importantly, most of the discussed GAG-dependent embryonic defects occur at times when cells secrete an abundance of extracellular matrix (ECM). For some of these

mutants, individual phenotypes have been linked to alterations in growth factor signaling; in particular loss of *ext2/dak* reduced Fgf and Wnt signaling as assessed by expression of downstream targets [97]. In addition, a recent study by Yost and co-workers, showed that reducing 2-O sulfation of HS GAGs following depletion of zebrafish 2-O sulfotransferase diminished Wnt signaling and Wnt-dependent initiation of epiboly. Reactivation of β -catenin, an intracellular component of canonical Wnt-signaling, rescued this defect [98]. In other mutants, including those affecting heart valve development, it is unclear to what degree the phenotypes are due to downstream effects on signal transduction or alterations in the physiochemical properties of the ECM that result when the GAGs or the protein cores are depleted.

Modeling glycosylation disorders in zebrafish

Several groups have also now employed reverse genetic approaches both to directly ascertain the functional roles of glycans in zebrafish and to model glycosylation-related disorders. Congenital muscular dystrophies (CMDs) that arise due to defective glycosylation of α -dystroglycan are attractive targets for study since their primary phenotypes in muscle and brain can be readily investigated using the zebrafish system. Genomic studies demonstrated that the genes required for functional glycosylation of dystroglycan are conserved in zebrafish [99, 100]. Furthermore, morpholino-based reduction of the Large2 protein in embryos results in a loss of IHH6 reactivity, suggesting that the O-mannosylation of dystroglycan is altered [100]. Similar results were noted in fukutin-knockdown embryos. Fkrp knockdown results in muscle defects as well as neuronal and eye abnormalities, which are accompanied by a reduction in DG glycosylation and laminin binding [101, 102]. Interestingly, involvement of the unfolded protein response was also reported in *fkrp* morphants [103]. Injection of antisense morpholino oligonucleotides of *pomt1* and *pomt2* resulted in several severe phenotypes including bent body, edematous pericardium and abnormal eye pigmentation [104].

In addition to CMDs, the human disorder, mucopolisaccharidosis II (ML-II), which results from impaired mannose 6-phosphate (Man-6-P) biosynthesis, has also been studied in zebrafish. While zebrafish express all the components of this carbohydrate-based lysosomal targeting pathway, some intriguing differences with regard to the substrate specificity of the initiating enzyme in Man-6-P biosynthesis, GlcNAc-1-phosphotransferase (*gnptab*), have been noted. In particular, some of the acid hydrolases that bear Man-6-P modified glycans in mammals (ex. acid- α -glucosidase) do not appear to be Man-6-P modified in zebrafish [105]. Morpholino-based depletion of GlcNAc-1-phosphotransferase resulted in several phenotypes consistent with the human disorder including

cardiac and craniofacial defects [106]. These phenotypes were associated with altered TGF- β signaling and excessive deposition of type II collagen. Altered TGF-beta signaling has also been noted in zebrafish embryos with reduced expression of the lysosomal hydrolase, iduronate 2-sulfatase [107]. More recently, sustained and increased activity of one Man-6-P modified hydrolase, cathepsin K, was shown to play a central role in the cartilage phenotypes of ML-II morphant embryos [108]. Zebrafish models of lysosomal diseases and other inherited disorders such as the congenital disorders of glycosylation (CDG) will represent a valuable new tool to explore their pathogenesis.

Conclusion

The function of glycans during embryogenesis will continue to be revealed as more zebrafish mutants are identified and characterized, and researchers in the areas of glycobiology and zebrafish development find common ground. We also anticipate an increased use of zebrafish to model glycosylation-related disorders in the years to come. This effort will likely be aided by the isolation of additional mutants, generated by TILLING-based screens and other comprehensive forward and reverse mutagenic efforts. Caution in interpreting initially negative results or cases where phenotypes do not correlate with loss of enzymatic function is warranted since the genome wide duplications that have occurred in zebrafish may have created significant functional redundancy of many glycosylation-related genes. Moreover, because many glycosylation disorders arise due to point mutations that alter the function (but not expression) of enzymes, methods that reduce or eliminate wild type enzymes, such as morpholino knockdown, may not be effective at faithfully recapitulating the disease phenotypes noted in patients or “knock-in” mouse models. In these cases, transgenic reintroduction of altered gene sequences may prove more useful. Parallel efforts to understand how substrate biosynthesis and glycan expression is regulated in the zebrafish are also needed. This is particularly true in light of the dynamic nature of monosaccharide and lipid metabolism during early embryonic development and the influence of yolk-derived metabolites. As the range of glycan structures in zebrafish become more clearly elucidated, this system will represent an ideal platform to study the functional relevance of rare and unusual glycans.

References

1. Mullins, M.C., Hammerschmidt, M., Haffter, P., Nusslein-Volhard, C.: Large-scale mutagenesis in the zebrafish: in search of genes controlling development in a vertebrate. *Curr. Biol.* **4**(3), 189–202 (1994)

2. Haffter, P., *et al.*: The identification of genes with unique and essential functions in the development of the zebrafish, *Danio rerio*. *Development* **123**, 1–36 (1996)
3. Granato, M., Nusslein-Volhard, C.: Fishing for genes controlling development. *Curr. Opin. Genet. Dev.* **6**(4), 461–468 (1996)
4. Peterson, R.T., Macrae, C.A.: Systematic approaches to toxicology in the zebrafish. *Annu. Rev. Pharmacol. Toxicol.* **52**, 433–453 (2012)
5. Zon, L.I., Peterson, R.T.: *In vivo* drug discovery in the zebrafish. *Nat Rev Drug Discov* **4**(1), 35–44 (2005)
6. MacRae, C.A., Peterson, R.T.: Zebrafish-based small molecule discovery. *Chem. Biol.* **10**(10), 901–908 (2003)
7. Baier, H., *et al.*: Genetic dissection of the retinotectal projection. *Development* **123**, 415–425 (1996)
8. Brand, M., *et al.*: Mutations in zebrafish genes affecting the formation of the boundary between midbrain and hindbrain. *Development* **123**, 179–190 (1996)
9. Brand, M., *et al.*: Mutations affecting development of the midline and general body shape during zebrafish embryogenesis. *Development* **123**, 129–142 (1996)
10. Chen, J.N., *et al.*: Mutations affecting the cardiovascular system and other internal organs in zebrafish. *Development* **123**, 293–302 (1996)
11. Furutani-Seiki, M., *et al.*: Neural degeneration mutants in the zebrafish, *Danio rerio*. *Development* **123**, 229–239 (1996)
12. Granato, M., *et al.*: Genes controlling and mediating locomotion behavior of the zebrafish embryo and larva. *Development* **123**, 399–413 (1996)
13. Hammerschmidt, M., *et al.*: Mutations affecting morphogenesis during gastrulation and tail formation in the zebrafish, *Danio rerio*. *Development* **123**, 143–151 (1996)
14. Heisenberg, C.P., *et al.*: Genes involved in forebrain development in the zebrafish, *Danio rerio*. *Development* **123**, 191–203 (1996)
15. Jiang, Y.J., *et al.*: Mutations affecting neurogenesis and brain morphology in the zebrafish, *Danio rerio*. *Development* **123**, 205–216 (1996)
16. Kane, D.A., *et al.*: The zebrafish epiboly mutants. *Development* **123**, 47–55 (1996)
17. Kane, D.A., *et al.*: The zebrafish early arrest mutants. *Development* **123**, 57–66 (1996)
18. Karlstrom, R.O., *et al.*: Zebrafish mutations affecting retinotectal axon pathfinding. *Development* **123**, 427–438 (1996)
19. Kelsh, R.N., *et al.*: Zebrafish pigmentation mutations and the processes of neural crest development. *Development* **123**, 369–389 (1996)
20. Mullins, M.C., *et al.*: Genes establishing dorsoventral pattern formation in the zebrafish embryo: the ventral specifying genes. *Development* **123**, 81–93 (1996)
21. Odenthal, J., *et al.*: Mutations affecting the formation of the notochord in the zebrafish, *Danio rerio*. *Development* **123**, 103–115 (1996)
22. Piotrowski, T., *et al.*: Jaw and branchial arch mutants in zebrafish II: anterior arches and cartilage differentiation. *Development* **123**, 345–356 (1996)
23. Ransom, D.G., *et al.*: Characterization of zebrafish mutants with defects in embryonic hematopoiesis. *Development* **123**, 311–319 (1996)
24. Schilling, T.F., *et al.*: Jaw and branchial arch mutants in zebrafish I: branchial arches. *Development* **123**, 329–344 (1996)
25. Trowe, T., *et al.*: Mutations disrupting the ordering and topographic mapping of axons in the retinotectal projection of the zebrafish, *Danio rerio*. *Development* **123**, 439–450 (1996)
26. van Eeden, F.J., *et al.*: Mutations affecting somite formation and patterning in the zebrafish, *Danio rerio*. *Development* **123**, 153–164 (1996)
27. van Eeden, F.J., *et al.*: Genetic analysis of fin formation in the zebrafish, *Danio rerio*. *Development* **123**, 255–262 (1996)
28. Whitfield, T.T., *et al.*: Mutations affecting development of the zebrafish inner ear and lateral line. *Development* **123**, 241–254 (1996)
29. Amsterdam, A., *et al.*: A large-scale insertional mutagenesis screen in zebrafish. *Genes Dev.* **13**(20), 2713–2724 (1999)
30. Stainier, D.Y., *et al.*: Mutations affecting the formation and function of the cardiovascular system in the zebrafish embryo. *Development* **123**, 285–292 (1996)
31. Pack, M., *et al.*: Mutations affecting development of zebrafish digestive organs. *Development* **123**, 321–328 (1996)
32. Feitsma, H., Cuppen, E.: Zebrafish as a cancer model. *Mol. Cancer Res* **6**(5), 685–694 (2008)
33. Feitsma, H., Kuiper, R.V., Korving, J., Nijman, I.J., Cuppen, E.: Zebrafish with mutations in mismatch repair genes develop neurofibromas and other tumors. *Cancer Res.* **68**(13), 5059–5066 (2008)
34. Drummond, I.A.: Kidney development and disease in the zebrafish. *J. Am. Soc. Nephrol.* **16**(2), 299–304 (2005)
35. Rubinstein, A.L.: Zebrafish: from disease modeling to drug discovery. *Curr Opin Drug Discov Devel* **6**(2), 218–223 (2003)
36. Lieschke, G.J., Currie, P.D.: Animal models of human disease: zebrafish swim into view. *Nat. Rev. Genet.* **8**(5), 353–367 (2007)
37. Guerardel, Y., Chang, L.Y., Maes, E., Huang, C.J., Khoo, K.H.: Glycomic survey mapping of zebrafish identifies unique sialylation pattern. *Glycobiology* **16**(3), 244–257 (2006)
38. Chang, L.Y., *et al.*: Developmental regulation of oligosialylation in zebrafish. *Glycoconj. J.* **26**(3), 247–261 (2009)
39. Chang, L.Y., *et al.*: Molecular cloning and characterization of the expression pattern of the zebrafish alpha2, 8-sialyltransferases (ST8Sia) in the developing nervous system. *Glycoconj. J.* **26**(3), 263–275 (2009)
40. Harduin-Lepers, A., *et al.*: Evolutionary history of the alpha2,8-sialyltransferase (ST8Sia) gene family: tandem duplications in early deuterostomes explain most of the diversity found in the vertebrate ST8Sia genes. *BMC Evol. Biol.* **8**, 258 (2008)
41. Bentreop, J., Marx, M., Schattschneider, S., Rivera-Milla, E., Bastmeyer, M.: Molecular evolution and expression of zebrafish St8SiaIII, an alpha-2,8-sialyltransferase involved in myotome development. *Dev. Dyn.* **237**(3), 808–818 (2008)
42. Marx, M., Rivera-Milla, E., Stummeyer, K., Gerardy-Schahn, R., Bastmeyer, M.: Divergent evolution of the vertebrate polysialyltransferase Stx and Pst genes revealed by fish-to-mammal comparison. *Dev. Biol.* **306**(2), 560–571 (2007)
43. Vanbeselaere, J., *et al.*: Mapping the expressed glycome and glycosyltransferases of zebrafish liver cells as a relevant model system for glycosylation studies. *J. Proteome Res* **11**(4), 2164–2177 (2012)
44. Langhauser, M., *et al.*: Ncam1a and Ncam1b: two carriers of polysialic acid with different functions in the developing zebrafish nervous system. *Glycobiology* **22**(2), 196–209 (2012)
45. Schaper, W., *et al.*: Identification and Biochemical Characterization of Two Functional CMP-Sialic Acid Synthetases in *Danio rerio*. *J. Biol. Chem.* **287**(16), 13239–13248 (2012)
46. Takemoto, T., Natsuka, S., Nakakita, S., Hase, S.: Expression of complex-type N-glycans in developmental periods of zebrafish embryo. *Glycoconj. J.* **22**(1–2), 21–26 (2005)
47. Kageyama, N., Natsuka, S., Hase, S.: Molecular cloning and characterization of two zebrafish alpha(1,3) fucosyltransferase genes developmentally regulated in embryogenesis. *J. Biochem.* **125**(4), 838–845 (1999)
48. Moriguchi, K., *et al.*: Free oligosaccharides with Lewis x structure expressed in the segmentation period of zebrafish embryo. *J. Biochem.* **142**(2), 213–227 (2007)

49. Souza, A.R., *et al.*: Chondroitin sulfate and keratan sulfate are the major glycosaminoglycans present in the adult zebrafish *Danio rerio* (Chordata-Cyprinidae). *Glycoconj. J.* **24**(9), 521–530 (2007)
50. Zhang, F., *et al.*: Structural characterization of glycosaminoglycans from zebrafish in different ages. *Glycoconj. J.* **26**(2), 211–218 (2009)
51. Semino, C.E., Specht, C.A., Raimondi, A., Robbins, P.W.: Homologs of the *Xenopus* developmental gene DG42 are present in zebrafish and mouse and are involved in the synthesis of Nod-like chitin oligosaccharides during early embryogenesis. *Proc. Natl. Acad. Sci. U. S. A.* **93**(10), 4548–4553 (1996)
52. Bakkers, J., *et al.*: An important developmental role for oligosaccharides during early embryogenesis of cyprinid fish. *Proc. Natl. Acad. Sci. U. S. A.* **94**(15), 7982–7986 (1997)
53. Semino, C.E., Allende, M.L.: Chitin oligosaccharides as candidate patterning agents in zebrafish embryogenesis. *Int. J. Dev. Biol.* **44**(2), 183–193 (2000)
54. Snaar-Jagalska, B.E., Krens, S.F., Robina, I., Wang, L.X., Spaink, H.P.: Specific activation of ERK pathways by chitin oligosaccharides in embryonic zebrafish cell lines. *Glycobiology* **13**(10), 725–732 (2003)
55. van Asselt, E., de Graaf, F., Smit-Onel, M.J., van Raamsdonk, W.: Spinal neurons in the zebrafish labeled with fluoro-gold and wheat-germ agglutinin. *Neuroscience* **43**(2–3), 611–622 (1991)
56. Becker, K.A., Hart, N.H.: Reorganization of filamentous actin and myosin-II in zebrafish eggs correlates temporally and spatially with cortical granule exocytosis. *J Cell Sci* **112**(Pt 1), 97–110 (1999)
57. Lugo-Villarino, G., *et al.*: Identification of dendritic antigen-presenting cells in the zebrafish. *Proc. Natl. Acad. Sci. U. S. A.* **107**(36), 15850–15855 (2010)
58. Laughlin, S.T., Baskin, J.M., Amacher, S.L., Bertozzi, C.R.: *In vivo* imaging of membrane-associated glycans in developing zebrafish. *Science* **320**(5876), 664–667 (2008)
59. Baskin, J.M., Dehnert, K.W., Laughlin, S.T., Amacher, S.L., Bertozzi, C.R.: Visualizing enveloping layer glycans during zebrafish early embryogenesis. *Proc. Natl. Acad. Sci. U. S. A.* **107**(23), 10360–10365 (2010)
60. Dehnert, K.W., *et al.*: Imaging the Sialome during Zebrafish Development with Copper-Free Click Chemistry. *ChemBioChem* **13**(3), 353–357 (2012)
61. Dehnert, K.W., *et al.*: Metabolic labeling of fucosylated glycans in developing zebrafish. *ACS Chem. Biol.* **6**(6), 547–552 (2011)
62. Zheng, T., *et al.*: Tracking N-acetylglucosamine on cell-surface glycans *in vivo*. *Angew Chem Int Ed Engl* **50**(18), 4113–4118 (2011)
63. Jiang, H., *et al.*: Imaging glycans in zebrafish embryos by metabolic labeling and bioorthogonal click chemistry. *J Vis Exp* **52**, 2686 (2011). doi:10.3791/2686
64. Soriano Del Amo, D., *et al.*: Biocompatible copper(I) catalysts for *in vivo* imaging of glycans. *J. Am. Chem. Soc.* **132**(47), 16893–16899 (2010)
65. Panzer, J.A., *et al.*: Neuromuscular synaptogenesis in wild-type and mutant zebrafish. *Dev. Biol.* **285**(2), 340–357 (2005)
66. Song, Y., *et al.*: Neural and synaptic defects in slytherin, a zebrafish model for human congenital disorders of glycosylation. *PLoS One* **5**(10), e13743 (2010)
67. Stanley, P., Okajima, T.: Roles of glycosylation in Notch signaling. *Curr. Top. Dev. Biol.* **92**, 131–164 (2010)
68. Jafar-Nejad, H., Leonardi, J., Fernandez-Valdivia, R.: Role of glycans and glycosyltransferases in the regulation of Notch signaling. *Glycobiology* **20**(8), 931–949 (2010)
69. Haines, N., Irvine, K.D.: Glycosylation regulates Notch signaling. *Nat. Rev. Mol. Cell Biol.* **4**(10), 786–797 (2003)
70. Haltiwanger, R.S.: Regulation of signal transduction pathways in development by glycosylation. *Curr. Opin. Struct. Biol.* **12**(5), 593–598 (2002)
71. Ohata, S., *et al.*: Neuroepithelial cells require fucosylated glycans to guide the migration of vagus motor neuron progenitors in the developing zebrafish hindbrain. *Development* **136**(10), 1653–1663 (2009)
72. Seth, A., Machingo, Q.J., Fritz, A., Shur, B.D.: Core fucosylation is required for midline patterning during zebrafish development. *Dev. Dyn.* **239**(12), 3380–3390 (2010)
73. Machingo, Q.J., Fritz, A., Shur, B.D.: A beta1,4-galactosyltransferase is required for convergent extension movements in zebrafish. *Dev. Biol.* **297**(2), 471–482 (2006)
74. Machingo, Q.J., Fritz, A., Shur, B.D.: A beta1,4-galactosyltransferase is required for Bmp2-dependent patterning of the dorsoventral axis during zebrafish embryogenesis. *Development* **133**(11), 2233–2241 (2006)
75. Craig, S.E., *et al.*: The zebrafish galectin Drgal1-l2 is expressed by proliferating Muller glia and photoreceptor progenitors and regulates the regeneration of rod photoreceptors. *Invest Ophthalmol Vis Sci* **51**(6), 3244–3252 (2010)
76. Ahmed, H., Du, S.J., Vasta, G.R.: Knockdown of a galectin-1-like protein in zebrafish (*Danio rerio*) causes defects in skeletal muscle development. *Glycoconj. J.* **26**(3), 277–283 (2009)
77. Ahmed, H., Vasta, G.R.: Unlike mammalian GRIFIN, the zebrafish homologue (DrGRIFIN) represents a functional carbohydrate-binding galectin. *Biochem. Biophys. Res. Commun.* **371**(3), 350–355 (2008)
78. Vasta, G.R., Ahmed, H., Du, S., Henrikson, D.: Galectins in teleost fish: Zebrafish (*Danio rerio*) as a model species to address their biological roles in development and innate immunity. *Glycoconj. J.* **21**(8–9), 503–521 (2004)
79. Ahmed, H., Du, S.J., O’Leary, N., Vasta, G.R.: Biochemical and molecular characterization of galectins from zebrafish (*Danio rerio*): notochord-specific expression of a prototype galectin during early embryogenesis. *Glycobiology* **14**(3), 219–232 (2004)
80. Marx, M., Rutishauser, U., Bastmeyer, M.: Dual function of polysialic acid during zebrafish central nervous system development. *Development* **128**(24), 4949–4958 (2001)
81. Webster, D.M., *et al.*: O-GlcNAc modifications regulate cell survival and epiboly during zebrafish development. *BMC Dev. Biol.* **9**, 28 (2009)
82. Willer, G.B., Lee, V.M., Gregg, R.G., Link, B.A.: Analysis of the Zebrafish perplexed mutation reveals tissue-specific roles for *de novo* pyrimidine synthesis during development. *Genetics* **170**(4), 1827–1837 (2005)
83. Peal, D.S., Burns, C.G., Macrae, C.A., Milan, D.: Chondroitin sulfate expression is required for cardiac atrioventricular canal formation. *Dev. Dyn.* **238**(12), 3103–3110 (2009)
84. Becker, C.G., Becker, T.: Repellent guidance of regenerating optic axons by chondroitin sulfate glycosaminoglycans in zebrafish. *J. Neurosci.* **22**(3), 842–853 (2002)
85. Bernhardt, R.R., Schachner, M.: Chondroitin sulfates affect the formation of the segmental motor nerves in zebrafish embryos. *Dev. Biol.* **221**(1), 206–219 (2000)
86. Zoeller, J.J., *et al.*: A central role for decorin during vertebrate convergent extension. *J. Biol. Chem.* **284**(17), 11728–11737 (2009)
87. De Cat, B., *et al.*: Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. *J Cell Biol* **163**(3), 625–635 (2003)
88. Arrington, C.B., Yost, H.J.: Extra-embryonic syndecan 2 regulates organ primordia migration and fibrillogenesis throughout the zebrafish embryo. *Development* **136**(18), 3143–3152 (2009)
89. Kramer, K.L., Yost, H.J.: Ectodermal syndecan-2 mediates left-right axis formation in migrating mesoderm as a cell-nonautonomous Vg1 cofactor. *Dev Cell* **2**(1), 115–124 (2002)

90. Eames, B.F., *et al.*: UDP xylose synthase 1 is required for morphogenesis and histogenesis of the craniofacial skeleton. *Dev. Biol.* **341**(2), 400–415 (2010)
91. Walsh, E.C., Stainier, D.Y.: UDP-glucose dehydrogenase required for cardiac valve formation in zebrafish. *Science* **293**(5535), 1670–1673 (2001)
92. Eames, B.F., *et al.*: Mutations in *fam20b* and *xytl1* reveal that cartilage matrix controls timing of endochondral ossification by inhibiting chondrocyte maturation. *PLoS Genet* **7**(8), e1002246 (2011)
93. Lee, J.S., *et al.*: Axon sorting in the optic tract requires HSPG synthesis by *ext2* (*dackel*) and *extl3* (*boxer*). *Neuron* **44**(6), 947–960 (2004)
94. Clement, A., *et al.*: Regulation of zebrafish skeletogenesis by *ext2/dackel* and *papst1/pinscher*. *PLoS Genet* **4**(7), e1000136 (2008)
95. Mizumoto, S., *et al.*: Chondroitin 4-O-sulfotransferase-1 is required for somitic muscle development and motor axon guidance in zebrafish. *Biochem. J.* **419**(2), 387–399 (2009)
96. Busch-Nentwich, E., Sollner, C., Roehl, H., Nicolson, T.: The deafness gene *dfna5* is crucial for *ugdh* expression and HA production in the developing ear in zebrafish. *Development* **131**(4), 943–951 (2004)
97. Norton, W.H., Ledin, J., Grandel, H., Neumann, C.J.: HSPG synthesis by zebrafish *Ext2* and *Extl3* is required for *Fgf10* signalling during limb development. *Development* **132**(22), 4963–4973 (2005)
98. Cadwalader, E. L., Condic, M. L., Yost, H. J.: 2-O-sulfotransferase regulates Wnt signaling, cell adhesion and cell cycle during zebrafish epiboly. *Development* (2012)
99. Grewal, P.K., McLaughlan, J.M., Moore, C.J., Browning, C.A., Hewitt, J.E.: Characterization of the LARGE family of putative glycosyltransferases associated with dystroglycanopathies. *Glycobiology* **15**(10), 912–923 (2005)
100. Moore, C.J., Goh, H.T., Hewitt, J.E.: Genes required for functional glycosylation of dystroglycan are conserved in zebrafish. *Genomics* **92**(3), 159–167 (2008)
101. Thornhill, P., Bassett, D., Lochmuller, H., Bushby, K., Straub, V.: Developmental defects in a zebrafish model for muscular dystrophies associated with the loss of fukutin-related protein (FKRP). *Brain* **131**(Pt 6), 1551–1561 (2008)
102. Wood, A.J., *et al.*: Abnormal vascular development in zebrafish models for fukutin and FKRP deficiency. *Hum. Mol. Genet.* **20**(24), 4879–4890 (2011)
103. Lin, Y.Y., *et al.*: Zebrafish Fukutin family proteins link the unfolded protein response with dystroglycanopathies. *Hum. Mol. Genet.* **20**(9), 1763–1775 (2011)
104. Avsar-Ban, E., *et al.*: Protein O-mannosylation is necessary for normal embryonic development in zebrafish. *Glycobiology* **20**(9), 1089–1102 (2010)
105. Fan, X., Klein, M., Flanagan-Steet, H.R., Steet, R.: Selective yolk deposition and mannose phosphorylation of lysosomal glycosidases in zebrafish. *J. Biol. Chem.* **285**(43), 32946–32953 (2010)
106. Flanagan-Steet, H., Sias, C., Steet, R.: Altered chondrocyte differentiation and extracellular matrix homeostasis in a zebrafish model for mucopolipidosis II. *Am. J. Pathol.* **175**(5), 2063–2075 (2009)
107. Moro, E., *et al.*: A novel functional role of iduronate-2-sulfatase in zebrafish early development. *Matrix Biol* **29**(1), 43–50 (2010)
108. Petrey, A.C., *et al.*: Excessive activity of cathepsin K is associated with cartilage defects in a zebrafish model of mucopolipidosis II. *Dis Model Mech* **5**(2), 177–190 (2012)